Evidence map›Paper›PMID 28718667›Full record

ArticleNutrition and cancer

Hydroxytyrosol Induces Apoptosis and Cell Cycle Arrest and Suppresses Multiple Oncogenic Signaling Pathways in Prostate Cancer Cells.

Haseeb Zubair, Arun Bhardwaj, Aamir Ahmad, Sanjeev Kumar Srivastava, Mohammad Aslam Khan, Girijesh Kumar Patel, Seema Singh, Ajay Partap Singh

Abstract read
In one paragraph

Article in Nutrition and cancer. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. A comprehensive review ofRSC advances · 2026
    Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Therapeutic Potential of Plant Phenolic Acids Combating Cancer Drug Resistance.Recent advances in food, nutrition & agriculture · 2026
    Review
  10. Review
  11. Anticancer Effects and Phytochemical Profile ofPharmaceuticals (Basel, Switzerland) · 2025
    Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Olive mill wastewater: From by-product to smart antioxidant material.International journal of pharmaceutics: X · 2024
    Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Haseeb Zubaira Department of Oncologic Sciences , Mitchell Cancer Institute, University of South Alabama , Mobile , Alabama , USA.
Arun Bhardwaja Department of Oncologic Sciences , Mitchell Cancer Institute, University of South Alabama , Mobile , Alabama , USA.
Aamir Ahmada Department of Oncologic Sciences , Mitchell Cancer Institute, University of South Alabama , Mobile , Alabama , USA.
Sanjeev Kumar Srivastavaa Department of Oncologic Sciences , Mitchell Cancer Institute, University of South Alabama , Mobile , Alabama , USA.
Mohammad Aslam Khana Department of Oncologic Sciences , Mitchell Cancer Institute, University of South Alabama , Mobile , Alabama , USA.
Girijesh Kumar Patela Department of Oncologic Sciences , Mitchell Cancer Institute, University of South Alabama , Mobile , Alabama , USA.
Seema Singha Department of Oncologic Sciences , Mitchell Cancer Institute, University of South Alabama , Mobile , Alabama , USA.
Ajay Partap Singha Department of Oncologic Sciences , Mitchell Cancer Institute, University of South Alabama , Mobile , Alabama , USA.
University of South Alabama · USUSA Mitchell Cancer Institute · US

Funding

Molecular determinant of racial disparity in prostate cancerU01CA185490 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI SINGH, AJAY PRATAP · 2014 to 2018
$1.7M
NCI NIH HHS U01 CA185490
6 · The paper itself

Abstract

scopeHydroxytyrosol (HT), a polyphenol from olives, is a potential anticancer agent. This study was designed to evaluate the anticancer activity of HT against prostate cancer cells, and the mechanism thereof. METHODS AND

resultsTreatment of LNCaP and C4-2 prostate cancer cells with HT resulted in a dose-dependent inhibition of proliferation. This was in contrast to HT's ineffectiveness against normal prostate epithelial cells RWPE1 and PWLE2, suggesting cancer-cell-specific effect. HT induced G1/S cell cycle arrest, with inhibition of cyclins D1/E and cdk2/4 and induction of inhibitory p21/p27. HT also induced apoptosis, as confirmed by flow cytometry, caspase activation, PARP cleavage, and BAX/Bcl-2 ratio. It inhibited the phosphorylation of Akt/STAT3, and induced cytoplasmic retention of NF-κB, which may explain its observed effects. Finally, HT inhibited androgen receptor (AR) expression and the secretion of AR-responsive prostate-specific antigen.

conclusionCastration-resistant prostate cancers retain AR signaling and are often marked by activated Akt, NF-κB, and STAT3 signaling. Our results establish a pleiotropic activity of HT against these oncogenic signaling pathways. Combined with its nontoxic effects against normal cells, our results support further testing of HT for prostate cancer therapy.

Indexed as

AntioxidantsApoptosisbcl-2-Associated X ProteinCaspase 3Caspase 7Cell Cycle CheckpointsCell Line, TumorCell ProliferationCell SurvivalCyclin D1Cyclin EEpithelial CellsHumansMaleNF-kappa BOncogene Proteins3,4-dihydroxyphenylethanolAntioxidantsAR protein, humanBAX protein, humanbcl-2-Associated X ProteinCASP3 protein, humanCASP7 protein, humanCaspase 3Caspase 7CCND1 protein, humanCCNE1 protein, humanCyclin D1Cyclin ENF-kappa BOncogene ProteinsPhenylethyl AlcoholProstate-Specific AntigenProto-Oncogene Proteins c-aktReceptors, AndrogenSTAT3 protein, humanSTAT3 Transcription Factor

Identifiers

PMID28718667
PMCPMC6125781
OpenAlexW2738089752

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.